article thumbnail

PPC Campaign Optimization for Pharma: Boosting ROI

Pharma Marketing Network

Leverage first-party data to refine retargeting strategies while maintaining HIPAA compliance. FDA and HIPAA Compliance in PPC Fair balance requirements Ads must include benefits and risks equally. No unapproved drug claims All claims must be backed by clinical research and FDA-approved labeling.

HIPAA 59
article thumbnail

Pharmaceutical Marketing in 2025: Trends, Tech, and Targeting That Matter Most

Pharma Marketing Network

As automation becomes smarter, ensuring HIPAA and GDPR compliance remains critical. Leveraging tools that enable real-time content approval and centralized tracking can prevent outdated messaging or off-label promotion. However, marketers must balance innovation with privacy.

HIPAA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How Has Social Media Advertising Changed in Pharma

Pharma Marketing Network

The emergence of HIPAA-compliant targeting technologies, HCP-specific segments, and improved analytics has made social platforms not just viable but essential for pharmaceutical marketing. While off-label promotion is still strictly regulated, unbranded awareness campaigns have found creative footing. It’s a strategic pillar.

HIPAA 52
article thumbnail

Email Marketing Campaigns for Pharma: Boost Engagement & Compliance

Pharma Marketing Network

Challenges in Pharma Email Marketing Pharma brands face unique barriers that other industries dont , such as: Strict compliance regulations (FDA, GDPR, HIPAA) that limit messaging. Drug names and indications must align with FDA-approved labeling. Email fatigue among HCPs and patients , leading to low open rates.

HIPAA 72
article thumbnail

NHC Comments on Medicare Drug Price Negotiation Program: Draft Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2027 and Manufacturer Effectuation of the Maximum Fair Price (MFP) in 2026 and 2027

Putting Patients First Blog

Enhance Dialogue-Based Engagement Clarify Required Disclosures Allow HIPAA Waivers if Feasible Clarify Speaker Selection Process Allow for Data Submissions After Sessions Increase Engagement. Off-label usage often emerges from real- world clinical practice and patient experiences, which might not be reflected in the guidelines.